Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN...

Full description

Bibliographic Details
Main Authors: Shuang Fan, Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
RUNX1-RUNX1T1
allogeneic hematopoietic stem cell transplantation
preemptive
interferon
donor lymphocyte infusion
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.773394/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.773394/full

Similar Items